JSSH
SRPT icon

J. Safra Sarasin Holding’s Sarepta Therapeutics SRPT Stock Holding History

J. Safra Sarasin Holding’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,567
Closed -$674K – 544
2025
Q1 		$674K Sell
10,567
-6,502
-38% -$684K 0.01% 383
2024
Q4 		$2.08M Buy
17,069
+1,566
+10% +$192K 0.04% 220
2024
Q3 		$1.94M Buy
15,503
+4,047
+35% +$559K 0.03% 214
2024
Q2 		$1.81M Buy
+11,456
New +$1.47M 0.03% 235

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

J. Safra Sarasin Holding's SRPT Position: Q2 2025 in Review

J. Safra Sarasin Holding sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 10,567 shares — an estimated $674K sold.

J. Safra Sarasin Holding first reported a position in SRPT in Q2 2024 and held it in 4 quarters. The position peaked at $2.08M in Q4 2024. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • J. Safra Sarasin Holding reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • J. Safra Sarasin Holding sold 10,567 Sarepta Therapeutics shares in Q2 2025, an estimated $674K.
  • J. Safra Sarasin Holding first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 4 quarters.
  • J. Safra Sarasin Holding's Sarepta Therapeutics position peaked at $2.08M in Q4 2024.
  • 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2025, filed 21 Jul 2025.